Preliminary experience with yttrium-90-labeled Rituximab (chimeric anti-CD20 antibody) in patients with relapsed and refractory B-cell NHL - a prospective trial

被引：0
|
作者：
Thakral, P. [1 ]
Lata, S. [1 ]
Singla, S. [1 ]
Sharma, A. [1 ]
Bal, C. [1 ]
Malhotra, A. [1 ]
机构：
[1] All India Inst Med Sci, New Delhi, India
来源：
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2012年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
OP690
引用
收藏
页码：S294 / S294
页数：1
相关论文
共 50 条
  • [31] RADIOIMMUNOTHERAPY OF REFRACTORY B-CELL LYMPHOMA WITH 131-I-ANTI-B1 (ANTI-CD20) ANTIBODY
    KAMINSKI, MS
    FENNER, M
    ZASADNY, KR
    MILIK, AW
    ROSS, CW
    FRANCIS, IR
    BURGESS, J
    ESTES, J
    CRAWFORD, S
    HODUL, P
    COOK, R
    REGAN, D
    PETRY, N
    GLENN, S
    BUTCHKO, G
    WAHL, RL
    CLINICAL RESEARCH, 1994, 42 (03): : A405 - A405
  • [32] Chimeric anti-CD20 monoclonal antibody (rituximab) plus G-CSF in relapsed B-cell-lymphoma:: A phase I/II clinical trial.
    van der Kolk, LE
    Grillo-López, AJ
    Gerritsen, W
    Jonkhoff, AR
    Baars, J
    van Oers, MHJ
    BLOOD, 1998, 92 (10) : 241B - 241B
  • [33] Phase I/II clinical trial to evaluate the safety and efficacy of a combination of a chimeric anti-CD20 monoclonal antibody (rituximab) and G-CSF given weekly to patients with relapsed B-cell lymphoma.
    vanderKolk, LE
    Gerritsen, W
    Baars, J
    Jonkhoff, AR
    vanOers, MHJ
    BLOOD, 1997, 90 (10) : 2284 - 2284
  • [34] A novel platform for radioimmunotherapy.: Extracorporeal depletion of biotinylated and 90Y-labeled anti-CD20 in patients with refractory B-cell lymphoma
    Tennvall, JG
    Lindén, O
    Garkavij, M
    Kurkus, J
    Cavallin-Ståhl, E
    Ohlsson, T
    Nilsson, R
    Sandberg, B
    Ljungberg, M
    Strand, SE
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2004, 31 : S221 - S221
  • [35] B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience
    Shaw, T
    Quan, J
    Totoritis, MC
    ANNALS OF THE RHEUMATIC DISEASES, 2003, 62 : 55 - 59
  • [36] Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with refractory idiopathic thrombocytopenic purpura.
    Braendstrup, P
    Pedersen, M
    Bjerrum, OW
    Nielsen, OJ
    Jensen, BA
    Clausen, NT
    Hansen, PB
    Andersen, I
    Schmidt, K
    Andersen, TM
    Peterslund, NA
    Birgens, HS
    Plesner, T
    Pedersen, BB
    Hasselbalch, HC
    BLOOD, 2003, 102 (11) : 298A - 298A
  • [37] Anti-CD20–atezolizumab–polatuzumab vedotin in relapsed/refractory follicular and diffuse large B-cell lymphoma
    Max S. Topp
    Herbert Eradat
    Axel Florschütz
    Andreas Hochhaus
    Tomasz Wrobel
    Jan Walewski
    Wanda Knopinska-Posluszny
    Abraham S. Kanate
    Ewa Lech-Maranda
    Uta Brunnberg
    Surya Chitra
    Tina G. Nielsen
    Gila Sellam
    Mahesh Shivhare
    Izidore S. Lossos
    Journal of Cancer Research and Clinical Oncology, 2023, 149 : 811 - 817
  • [38] Clinical Activity of REGN1979, a Bispecific Human, Anti-CD20 x Anti-CD3 Antibody, in Patients with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphoma (B-NHL)
    Bannerji, Rajat
    Allan, John N.
    Arnason, Jon E.
    Brown, Jennifer R.
    Advani, Ranjana H.
    Barnes, Jeffrey A.
    Ansell, Stephen M.
    O'Brien, Susan M.
    Chavez, Julio
    Duell, Johannes
    David, Kevin A.
    Martin, Peter
    Joyce, Robin M.
    Charnas, Robert
    Ambati, Srikanth R.
    Adriaens, Lieve
    Ufkin, Melanie
    Zhu, Min
    Li, Jingjin
    Gasparini, Peter
    Ibrahim, Anfal
    Jankovic, Vladimir
    Fiaschi, Nathalie
    Aina, Olulanu
    Zhang, Wen
    Deering, Raquel P.
    Hamon, Sara
    Thurston, Gavin
    Murphy, Andrew J.
    Weinreich, David M.
    Yancopoulos, George D.
    Lowy, Israel
    Sternberg, David
    Topp, Max S.
    BLOOD, 2019, 134
  • [39] The combination of milatuzumab, a humanized anti-CD74 antibody, and veltuzumab, a humanized anti-CD20 antibody, demonstrates activity in patients with relapsed and refractory B-cell non-Hodgkin lymphoma
    Christian, Beth A.
    Poi, Ming
    Jones, Jeffrey A.
    Porcu, Pierluigi
    Maddocks, Kami
    Flynn, Joseph M.
    Benson, Don M.
    Phelps, Mitch A.
    Wei, Lai
    Byrd, John C.
    Wegener, William A.
    Goldenberg, David M.
    Baiocchi, Robert A.
    Blum, Kristie A.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 169 (05) : 701 - 710
  • [40] Phase I and pharmacokinetics study of a novel anti-CD20 antibody, RO5072759 (GA101), in Japanese patients (Pts) with relapsed or refractory B-cell non-Hodgkin lymphoma (B-NHL) pretreated with rituximab
    Tobinai, K.
    Ogura, M.
    Hatake, K.
    Kobayashi, Y.
    Mori, M.
    Uchida, T.
    Suzuki, T.
    Terui, Y.
    Yokoyama, M.
    Hotta, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345